These events may contribute to allograft failure (e.g., nephrotoxicity, hypertension) or increase the risk of cardiovascular disorders (e.g., dyslipidemia, hypertension, post-transplant diabetes mellitus), as well as drug discontinuation, as seen in mTOR inhibitor-induced mouth ulcers. The gene discussed is MTOR; the disease is cardiovascular disorder.